CGeneTech (Suzhou, China) Co., Ltd., a biopharmaceutical company based in China, has reportedly secured a Series C financing round totaling RMB 100 million, led by Tongren Boda Investment. The capital raised will be strategically allocated towards the commercial-scale manufacturing and marketing efforts for its flagship product, centagliptin, a Category 1 drug nearing market launch. Additionally, the funds will support the clinical development of the company’s subsequent product pipelines.
Specializing in the research, development, and industrialization of high-quality, differentiated small molecule innovative drugs, CGeneTech has an extensive pipeline addressing conditions such as hypoglycemia, cancer, and autoimmune disorders. Centagliptin, a selective DPP-4 inhibitor, is positioned as a best-in-class hypoglycemic drug candidate. The company’s innovative therapeutics, including the CXCR4 antagonist CGT-1881 and the FGFR/VEGFR dual target inhibitor CGT-6321, have recently received clearance to commence clinical trials in the United States, underscoring CGeneTech’s commitment to advancing novel treatments for unmet medical needs. – Flcube.com
